Cilta-cel’s Submission on Track in the US, Europe, China, and Japan; Multiple Cilta-cel Clinical Updates Expected at ASCO and EHA 2021; Legend Q1 2021 Earnings Summary

On Tuesday, May 18, Legend released their Q1 2021 financial results (press release), highlighting that cilta-cel’s (BCMA CAR-T) US and EU regulatory approvals in r/r MM remain on track, with submissions in China and Japan anticipated in H2 2021. Furthermore, management confirmed that a number of cilta-cel clinical updates will be presented at ASCO and EHA 2021. Below, Celltelligence provides updated timelines for cilta-cel’s approval in the US and EU, while detailing cilta-cel’s upcoming clinical updates.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.